Compare
Lftd Partners Inc. vs Sunshine Biopharma Inc. vs BGM Group Ltd. vs Verrica Pharmaceuticals Inc.
| Latest fiscal year | Lftd Partners Inc. LIFD | Sunshine Biopharma Inc. SBFM | BGM Group Ltd. BGM | Verrica Pharmaceuticals Inc. VRCA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $36.92M | $36.31M | $37.92M | $35.58M |
| Revenue growth (YoY) | -1.1% | +4.1% | +51.1% | +370.2% |
| Gross margin | 34.2% | 33.8% | 16.6% | n/a |
| Operating margin | 2.5% | -17.2% | -33.2% | -34.2% |
| Net margin | -67.3% | -16.5% | -52.6% | -50.3% |
| Net income | -$24.86M | -$5.98M | -$19.94M | -$17.89M |
| EPS (Diluted) | -$1.68 | n/a | -$0.18 | -$1.68 |
| Operating cash flow | $1.32M | -$5.33M | -$2.37M | -$17.63M |
| Free cash flow | $1.20M | -$5.51M | -$3.94M | -$17.63M |
| Cash & equivalents | $1.77M | n/a | $9.82M | $30.15M |
| Total assets | $19.27M | $30.08M | $433.81M | $47.13M |
| Total liabilities | $6.64M | $7.04M | $41.92M | $22.39M |
| Shareholders' equity | $12.63M | $23.04M | $391.90M | $24.74M |
| Return on year-end equity | -196.8% | -25.9% | -5.1% | -72.3% |
| Shares outstanding | 14.82M | 4.91M | 200.62M | 17.18M |
Revenue, most recent five fiscal years
| Fiscal year | Lftd Partners Inc. | Sunshine Biopharma Inc. | BGM Group Ltd. | Verrica Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | $36.92M Ended 2025-12-31 | $36.31M Ended 2025-12-31 | $37.92M Ended 2025-09-30 | $35.58M Ended 2025-12-31 |
| 1 year earlier | $37.33M Ended 2024-12-31 | $34.87M Ended 2024-12-31 | $25.10M Ended 2024-09-30 | $7.57M Ended 2024-12-31 |
| 2 years earlier | $51.61M Ended 2023-12-31 | $24.09M Ended 2023-12-31 | $46.47M Ended 2023-09-30 | $5.12M Ended 2023-12-31 |
| 3 years earlier | $57.42M Ended 2022-12-31 | $4.35M Ended 2022-12-31 | $64.86M Ended 2022-09-30 | $9.03M Ended 2022-12-31 |
| 4 years earlier | $31.66M Ended 2021-12-31 | $228.4K Ended 2021-12-31 | $57.10M Ended 2021-09-30 | $12.00M Ended 2021-12-31 |